Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease

Conclusions: Darbepoetin alfa administered QM maintained Hb levels ≥11 g/dL in patients with CKD (not on dialysis) aged <65, 65 to 74, and ≥75 years. This treatment regimen may help optimize anemia management for older community-dwelling and long-term care patients.